Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Oksana Zavidij, Nicholas J. Haradhvala, Tarek H. Mouhieddine, +26

Nature Cancer

Hematological MalignancySingle Cell SequencingMedicineImmunologyPathology +12

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Alexandre Detappe, Hung V.‐T. Nguyen, Yivan Jiang, +10

Nature Nanotechnology

Hematological MalignancyMedicinePharmacologyImmune Checkpoint InhibitorMolecular Bottlebrush Prodrugs +9

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Romanos Sklavenitis‐Pistofidis, Michelle P. Aranha, Robert Redd, +36

Cancer Cell

Immune BiomarkersHematological MalignancyCancer ImmunosurveillanceAllergyAutoimmune Disease +7

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu J. Shen, Yuji Mishima, Jiantao Shi, +16

Blood

MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

Ankit K. Dutta, Jean-Baptiste Alberge, Elizabeth D. Lightbody, +21

Cancer Discovery

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

Sabrin Tahri, Tarek H. Mouhieddine, Robert Redd, +14

Blood Advances

ImmunologyPathologyIndolent NhlIncreased RiskImmunotherapy +15

Genomic landscape of multiple myeloma and its precursor conditions

Jean-Baptiste Alberge, Ankit K. Dutta, Andrea Poletti, +34

Nature Genetics

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

Yaya Chu, Gaurav Nayyar, Nang Kham Su, +7

Journal for ImmunoTherapy of Cancer

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, Omar Nadeem, Adam S. Sperling, +20

Blood

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety

Omar Nadeem, Robert Redd, Laura Stampleman, +14

Blood